FeNO by NIOX® USA Email Formats

Medical Equipment Manufacturing • Morrisville, North Carolina, United States • 1-10 Employees

FeNO by NIOX® USA Email Formats

FeNO by NIOX® USA uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@circassia.com), used 66.7% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@circassia.com	66.7%
{first name}.{last name}	john.doe@circassia.com	33.3%

Key Contact at FeNO by NIOX® USA

Troy Chaney

Director

Company overview

Headquarters	1100 Perimeter Park Drive, Suite 114, Morrisville, North Carolina 27560, US
Website	niox.com
NAICS	3391
Founded	2006
Employees	1-10

About FeNO by NIOX® USA

NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma. NIOX VERO® provides accurate and reliable results, allowing healthcare professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings. The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals. Overall, NIOX Group plc is the global leader in FeNO testing, with a strong reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma. References: 1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218. 2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1 3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173. 4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. 5. NIOX®. Data on File; MKT-DOF-007.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Entry

Director

Head

Employees by Department

FeNO by NIOX® USA has 2 employees across 2 departments.

Departments

Number of employees

Funding Data

FeNO by NIOX® USA has never raised funding before.

Frequently asked questions

FeNO by NIOX® USA is located in Morrisville, North Carolina, US.

FeNO by NIOX® USA was founded in 2006, making it 20 years old. The company has established itself as a significant player in its industry over this time.

FeNO by NIOX® USA has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at FeNO by NIOX® USA

Troy Chaney

Director

4.8

40,000 users